Welcome to our dedicated page for Quince SEC filings (Ticker: QNCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quince Therapeutics SEC filings document a rare-disease biotechnology issuer with QNCX common stock registered for trading on the Nasdaq Global Select Market. The filings cover its AIDE drug/device technology, eDSP clinical and regulatory disclosures, operating risks, capital structure and public-company governance.
Recent filings include Form 8-K material-event reports on debt settlement, Nasdaq continued-listing matters, a reverse stock split, board composition and related governance changes. Proxy materials describe director elections, executive compensation, equity awards, board committees and shareholder voting matters, while reporting notices address annual-report timing and required disclosure preparation.
Quince Therapeutics, Inc. reported that its President, Charles S. Ryan, received an employee stock option grant on January 23, 2026. The option gives him the right to buy 200,000 shares of common stock at an exercise price of $3.08 per share, with no cash paid for the grant itself.
The option vests in equal monthly installments over four years. According to the terms, 1/48th of the total shares vested on the grant date, and the remaining portions vest on the first day of each subsequent month so that all 200,000 shares are fully vested by December 1, 2029. After this grant, he directly beneficially owns 200,000 derivative securities in the form of these options.
Quince Therapeutics reported an insider equity award for executive Brendan Hannah, who serves as CBO, COO and CCO. On January 23, 2026, he received an employee stock option to buy 365,000 common shares at an exercise price of $3.08 per share, with the option expiring on January 23, 2036. The filing shows he holds 365,000 derivative securities after this grant, all owned directly.
The option vests in 48 equal monthly installments, with 1/48 of the shares vesting on the grant date and the remaining portions vesting on the first day of each subsequent month until full vesting on December 1, 2029. This reflects routine equity-based compensation for a senior officer rather than an open-market share purchase or sale.
Quince Therapeutics director Christopher J. Senner reported a grant of 21,810 stock options on January 2, 2026. The derivative award is a director stock option with a $3.00 exercise price and an expiration date of January 2, 2036, covering 21,810 shares of common stock. Following this grant, he beneficially owns 21,810 derivative securities directly.
The options will vest in equal quarterly installments over a one-year period. Senner elected to receive these options in lieu of the annual director cash retainer for 2026 under the company’s Outside Director Compensation Policy.
Quince Therapeutics director Margaret McLoughlin reported receiving a new stock option award. On 01/02/2026, she was granted a Director Stock Option (Right to Buy) covering 19,547 shares of common stock at an exercise price of $3 per share. The filing shows this as an acquisition of derivative securities held directly.
According to the footnote, the option vests in equal quarterly installments over a one-year period. McLoughlin elected to receive this stock option grant in lieu of the 2026 annual director cash retainer under the company’s Outside Director Compensation Policy, meaning this award represents her director compensation rather than an open-market transaction.
Quince Therapeutics director David Lamond reported receiving a grant of 29,423 director stock options on January 2, 2026. The options have an exercise price of $3.00 per share and relate to Quince common stock, with 29,423 derivative securities beneficially owned after the transaction. According to the filing, these options were granted in lieu of Lamond’s 2026 annual director cash retainer under the company’s Outside Director Compensation Policy and will vest in equal quarterly installments over a one-year period. The transaction is reported as a directly held derivative security.
Quince Therapeutics director June Bray received a new stock option grant. On 01/02/2026, Bray was granted director stock options covering 18,724 common shares at an exercise price of $3 per share, with no cash paid for the options themselves.
The options vest in equal quarterly installments over a one-year period, meaning the grant is tied to ongoing board service during 2026. Bray elected to receive this option award in lieu of the annual director cash retainer for 2026 under Quince Therapeutics' Outside Director Compensation Policy. Following this grant, Bray beneficially owns 18,724 derivative securities directly.
Quince Therapeutics, Inc. insider Dirk Thye, who serves as director and as CEO and CMO, reported a transfer of common shares dated 12/10/2025.
The reported transaction with code G involved 739,885 common shares at a stated price of $0, moving from direct to indirect beneficial ownership through the Thye Trust. After this transaction, Thye held 255,000 common shares directly and 739,885 common shares indirectly via the Thye Trust.
Quince Therapeutics reported third‑quarter results and disclosed “substantial doubt” about its ability to continue as a going concern. The company posted a Q3 net loss of $13.4 million and a nine‑month net loss of $44.5 million.
Cash, cash equivalents, and short‑term investments were $26.3 million as of September 30, 2025. Quince raised additional capital through an ATM program (net $4.3 million YTD) and a June 2025 private placement that issued common stock, pre‑funded warrants, and common warrants for gross proceeds of $11.5 million.
The balance sheet shows a $17.5 million current portion of the EIB loan (fair value) due August 2026, $61.2 million in long‑term contingent consideration tied to the EryDel acquisition, and $14.9 million warrant liabilities. Stockholders’ equity was $1.1 million. Shares outstanding were 55,681,490 as of November 6, 2025.
Quince Therapeutics, Inc. filed a current report to note that it has announced its financial results for the quarter ended September 30, 2025 and shared recent business highlights. The company states that these details are contained in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 to this report rather than being fully included in the body of the document.
Quince Therapeutics (QNCX) filed an 8-K under Regulation FD to correct an Investor Day statement. The company removed Slide 57 and the related video from its October 2, 2025 Virtual Investor Day and advised investors not to rely on the slide’s claim that IntraBio’s N-acetyl-L-leucine (NALL) “failed Phase 2 A-T study across all endpoints.”
Quince clarified its statement drew from a European Journal of Paediatric Neurology article describing a single-site study in ataxia-telangiectasia, which reported no significant improvements in ataxia symptoms or motor function, and was not the multi-site IntraBio Phase 2 Study.